| COVID-19 (death) |
Patient characteristics |
Smoking [History of smoking vs. None] |
Hazard ratio: 1.070 (0.880-1.310)
§ |
Petrilli
|
|
|
| COVID-19 (death) |
Patient characteristics |
Ethnicity [Unknown vs. Non-Hispanic White] |
Hazard ratio: 1.230 (0.820-1.830)
§ |
Petrilli
|
|
|
| COVID-19 (death) |
Patient characteristics |
Ethnicity [Mixed vs. Non-Hispanic White] |
Hazard ratio: 1.170 (0.860-1.600)
§ |
Petrilli
|
|
|
| COVID-19 (death) |
Patient characteristics |
Ethnicity [Hispanic vs. Non-Hispanic White] |
Hazard ratio: 1.210 (0.980-1.490)
§ |
Petrilli
|
|
|
| COVID-19 (death) |
Patient characteristics |
Ethnicity [Asian vs. Non-Hispanic White] |
Hazard ratio: 1.260 (0.910-1.750)
§ |
Petrilli
|
|
|
| COVID-19 (death) |
Patient characteristics |
Ethnicity [Non-Hispanic Black vs. Non-Hispanic White] |
Hazard ratio: 0.710 (0.530-0.940)
§ |
Petrilli
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with hydroxychloroquine + azithromycin vs. Not received] |
Hazard ratio: 0.460 (0.110-1.790)
§ |
Magagnoli
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with hydroxychloroquine vs. Not received] |
Hazard ratio: 0.750 (0.200-2.790)
§ |
Magagnoli
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with hydroxychloroquine + azithromycin vs. Not received] |
Hazard ratio: 1.250 (0.590-2.680)
§ |
Magagnoli
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with hydroxychloroquine vs. Not received] |
Hazard ratio: 2.110 (0.960-4.620)
§ |
Magagnoli
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with hydroxychloroquine + azithromycin vs. Not received] |
Hazard ratio: 1.310 (0.800-2.150)
§ |
Magagnoli
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with hydroxychloroquine vs. Not received] |
Hazard ratio: 1.830 (1.160-2.890)
§ |
Magagnoli
|
|
|
| COVID-19 (severe/critical) |
Treatment |
Treatment for COVID-19 [Treated with hydroxychloroquine + azithromycin vs. Not received] |
Hazard ratio: 1.120 (0.710-1.760)
§ |
Magagnoli
|
|
|
| COVID-19 (severe/critical) |
Treatment |
Treatment for COVID-19 [Treated with hydroxychloroquine vs. Not received] |
Hazard ratio: 1.270 (0.810-2.000)
§ |
Magagnoli
|
|
|
| COVID-19 (severe/critical) |
Treatment |
Treatment for COVID-19 [Treated with hydroxychloroquine + azithromycin vs. Not received] |
Hazard ratio: 1.090 (0.720-1.660)
§ |
Magagnoli
|
|
|
| COVID-19 (severe/critical) |
Treatment |
Treatment for COVID-19 [Treated with hydroxychloroquine vs. Not received] |
Hazard ratio: 1.190 (0.780-1.820)
§ |
Magagnoli
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with Azithromycin vs. Not received] |
Odds ratio: 5.490 (1.130-26.660)
|
Toraih
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with hydroxychloroquine vs. Not received] |
Odds ratio: 6.670 (2.000-22.220)
|
Toraih
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with Interferon vs. Not received] |
Odds ratio: 0.794 (0.285-2.210)
|
Toraih
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with Oseltamivir vs. Not received] |
Odds ratio: 0.974 (0.610-1.560)
|
Toraih
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with Lopinavir–Ritonavir vs. Not received] |
Odds ratio: 0.620 (0.097-3.970)
|
Toraih
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with Immunoglobulin vs. Not present] |
Odds ratio: 3.410 (1.900-6.140)
|
Toraih
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with Glucocorticoids vs. Not received] |
Odds ratio: 3.520 (2.510-4.930)
|
Toraih
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [treated with Antibiotics vs. Not received] |
Odds ratio: 3.360 (1.660-6.770)
|
Toraih
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with Antiviral drug vs. Not received] |
Odds ratio: 0.985 (0.670-1.450)
|
Toraih
|
|
|
| COVID-19 (death) |
Complications |
Sepsis [Present vs. Not present] |
Odds ratio: 220.000 (30.380-1593.170)
|
Toraih
|
|
|
| COVID-19 (death) |
Complications |
Shock [Present vs. Not present] |
Odds ratio: 36.900 (11.050-123.500)
|
Toraih
|
|
|
| COVID-19 (death) |
Complications |
Coagulopathy [Present vs. Not present] |
Odds ratio: 5.860 (2.830-12.130)
|
Toraih
|
|
|
| COVID-19 (death) |
Complications |
Heart failure [Present vs. Not present] |
Odds ratio: 4.150 (2.410-7.150)
|
Toraih
|
|
|
| COVID-19 (death) |
Complications |
Arrhythmia [Present vs. Not present] |
Odds ratio: 3.400 (1.670-6.940)
|
Toraih
|
|
|
| COVID-19 (death) |
Complications |
Liver injury [Present vs. Not present] |
Odds ratio: 2.930 (1.010-8.460)
|
Toraih
|
|
|
| COVID-19 (death) |
Complications |
Acute kidney Injury [Present vs. Not present] |
Odds ratio: 15.700 (8.240-30.200)
|
Toraih
|
|
|
| COVID-19 (death) |
Complications |
Pneumonia [Present vs. Not present] |
Odds ratio: 3.660 (2.040-6.570)
|
Toraih
|
|
|
| COVID-19 (death) |
Complications |
Acute respiratory distress syndrome [Present vs. Not present] |
Odds ratio: 34.800 (13.600-89.200)
|
Toraih
|
|
|
| COVID-19 (death) |
Comorbidities |
Cancer [Present vs. Not present] |
Odds ratio: 1.970 (1.410-2.760)
|
Toraih
|
|
|
| COVID-19 (death) |
Comorbidities |
Chronic kidney disease [Present vs. Not present] |
Odds ratio: 2.750 (1.770-4.280)
|
Toraih
|
|
|
| COVID-19 (death) |
Comorbidities |
Cardiovascular disease [Present vs. Not present] |
Odds ratio: 4.490 (2.720-7.400)
|
Toraih
|
|
|
| COVID-19 (death) |
Comorbidities |
COPD [Present vs. Not present] |
Odds ratio: 3.080 (2.360-4.030)
|
Toraih
|
|
|
| COVID-19 (death) |
Comorbidities |
Coronary heart disease [Present vs. Not present] |
Odds ratio: 3.420 (2.650-4.420)
|
Toraih
|
|
|
| COVID-19 (death) |
Comorbidities |
Diabetes [Present vs. Not present] |
Odds ratio: 1.880 (1.590-2.240)
|
Toraih
|
|
|
| COVID-19 (death) |
Comorbidities |
Hypertension [Present vs. Not present] |
Odds ratio: 2.220 (1.750-2.810)
|
Toraih
|
|
|
| COVID-19 (death) |
Symptoms |
Chest pain/tightness [Present vs. Not present] |
Odds ratio: 1.930 (1.140-3.280)
|
Toraih
|
|
|
| COVID-19 (death) |
Patient characteristics |
Gender [Male vs. Female] |
Odds ratio: 1.500 (1.340-1.690)
|
Toraih
|
|
|
| COVID-19 (severe/critical) |
Treatment |
Treatment for COVID-19 [Treated with dexamethasone vs. Usual care] |
Risk ratio: 0.650 (0.510-0.820)
§ |
Horby
|
|
|
| COVID-19 (severe/critical) |
Treatment |
Treatment for COVID-19 [Treated with dexamethasone vs. Usual care] |
Risk ratio: 0.800 (0.700-0.920)
§ |
Horby
|
|
|
| COVID-19 (severe/critical) |
Treatment |
Treatment for COVID-19 [Treated with dexamethasone vs. Usual care] |
Risk ratio: 1.220 (0.930-1.610)
§ |
Horby
|
|
|
| COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with dexamethasone vs. Usual care] |
Risk ratio: 0.910 (0.820-1.010)
§ |
Horby
|
|
|
| COVID-19 (severe/critical) |
Treatment |
Treatment for COVID-19 [Treated with dexamethasone vs. Usual care] |
Risk ratio: 0.760 (0.610-0.960)
§ |
Horby
|
|
|
| COVID-19 (severe/fatal) |
Treatment |
Treatment for COVID-19 [Treated with dexamethasone vs. Usual care] |
Risk ratio: 0.910 (0.820-1.000)
§ |
Horby
|
|
|
| Hospital discharge |
Treatment |
Treatment for COVID-19 [Treated with dexamethasone vs. Usual care] |
Risk ratio: 1.110 (1.040-1.190)
§ |
Horby
|
|
|